The general mood among these heavyweight investors is divided, with 43% leaning bullish and 21% bearish. Among these notable ...

Now, after his first year as the pharma’s new CEO, former AbbVie operating chief Robert Michael is captaining a company with few obstacles on the horizon—and picking up a sizable payday for ...